WuXi Biologics (Cayman) Inc. has been included in the 2025 MSCI Selection Indexes for the third consecutive year. This inclusion underscores the company's sustained commitment to sustainability and its leadership in the biopharmaceutical industry, as evidenced by its high ESG ratings and recognition in areas such as product safety, corporate governance, and climate change.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on June 20, 2025, and is solely responsible for the information contained therein.